XLON
REL
Market cap57bUSD
Jun 18, Last price
2,348.00GBP
1D
-3.97%
1Q
-5.85%
Jan 2017
62.04%
Name
Relx PLC
Chart & Performance
P/E
21.36
P/S
4.38
EPS
1.10
Div Yield, %
1.83%
Shrs. gr., 5y
-0.83%
Rev. gr., 5y
3.68%
Revenues
9.43b
+2.98%
Net income
1.93b
+8.59%
CFO
2.61b
+6.15%
Dividend
May 07, 202648 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in London, United Kingdom, and established in 1903, RELX PLC (which rebranded from Reed Elsevier PLC in July 2015) offers sophisticated information analytics and decision-support tools to professional and business clientele across North America, Europe, and other international markets. Its operations are organized into four distinct divisions. The Risk division specializes in delivering analytics and decision systems that blend public and industry-specific data with advanced technology and algorithms, enabling clients to evaluate and anticipate various risks. The Scientific, Technical & Medical segment furnishes essential information and analytical insights to institutions and professionals, facilitating scientific advancement and improvements in healthcare. Within the Legal segment, the company supplies legal, regulatory, and commercial information and analytics, empowering customers' decision-making processes and enhancing their productivity. Lastly, the Exhibitions segment manages events, integrating in-person experiences with data and digital technologies to assist clients in understanding markets, identifying products, and closing deals.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||